Bristol Myers Squibb's LAG-3/PD-1 Combination Therapy Receives IND Approval in China for Advanced Solid Tumors
Bristol-Myers Squibb
Biopharmaceutical and Nutritional Product R&D and Sales
The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) announced that Bristol-Myers Squibb (BMS) Company’s relatlimab/nivolumab fixed-dose combination injection has received implied approval for clinical trials, intended for development in advanced solid tumors.
Relatlimab is an anti-LAG-3 antibody. Previously, its combination therapy with the anti-PD-1 antibody nivolumab (Opdivo) met the primary endpoint of progression-free survival (PFS) in a phase 2/3 clinical trial in treatment-naive patients with metastatic or unresectable melanoma. This also marks the first phase 3 clinical trial globally to report the efficacy of an anti-LAG-3 antibody.
Screenshot source: CDE official website
*Disclaimer: This article was written by a contributor to Sina Medical News. The views expressed are solely those of the author and do not represent the position of Sina Medical News.